most popular cryptocurrencies Featured snippets

Baiyun Airport: The passenger throughput in the first November increased by 21.16% year-on-year. Baiyun Airport (600004) released the November production and operation data express on the evening of December 13th, and Baiyun Airport took 43,637 flights (sorties) in November, up by 12.94% year-on-year. Passenger throughput was 6,504,400 person-times, up by 19.94% year-on-year; The cargo and mail throughput was 212,100 tons, a year-on-year increase of 5.68%. Baiyun Airport took off and landed 465,983 sorties from January to November, up 12.05% year-on-year; The passenger throughput was 69.6674 million person-times, up by 21.16% year-on-year; The cargo and mail throughput was 2,161,300 tons, up 18.12% year-on-year.Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.Mitsubishi electric will invest $143.5 million to build a heat pump factory in the United States.

Hunan procuratorate prosecuted Wang Yonghong for alleged bribery and abuse of power according to law. Recently, the case of Wang Yonghong (deputy department level), former member of the Standing Committee of Shaoyang Municipal Committee of Hunan Province and former executive deputy mayor of the Municipal People's Government, was assigned jurisdiction by Hunan Provincial People's Procuratorate, and Loudi Municipal People's Procuratorate prosecuted Loudi Intermediate People's Court according to law. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Wang Yonghong of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. Loudi City People's Procuratorate sued the accusation that the defendant Wang Yonghong, as a national staff member, used his position to seek benefits for others and illegally accepted other people's property, with a huge amount; As a staff member of a state organ, he abuses his power, causing great losses to the interests of the state and the people. According to law, he should be investigated for criminal responsibility for accepting bribes and abusing his power.Guoxin Technology: Serialized chip products have been launched in the field of automotive electronic MCU. Guoxin Technology said in an investigation that the company has launched serialized chip products in the field of automotive electronic MCU in recent years, which has been welcomed by the market; Through the implementation of the strategy of "standing on the ground" and "overwhelming", this year, the company's automobile electronic MCU chip business has formed certain advantages, and obvious progress has been made in loading application and shipment volume. The product price is relatively stable, the fluctuation range is small, and the gross profit margin of the product remains relatively stable. In 2024, the company's BMS main control chip CCFC2007PT, high-end domain control chip CCFC3007PT, airbag ignition drive chip CCL1600B, etc. have all been used for loading/installing, and several manufacturers are developing at designated locations based on the above chips. In the future, with the increase of fixed-point mass production projects, shipments are expected to continue to grow.Dutch International: Britain's economic growth momentum has further slowed down, but the budget boost is coming. Dutch International Bank said that Britain's GDP fell again in October, although this may exaggerate the degree of recent economic slowdown. According to the bank's forecast of Britain's annual GDP in 2025, the British economy will surpass most western European countries next year. This may tell more about the economic health of other parts of continental Europe, but it also reflects the impact of the recent fiscal stimulus measures in Britain to a great extent. Compared with the budget of the last Conservative government, public expenditure has increased by about 60 billion pounds, accounting for more than 2% of GDP. Most of the increased expenditure will flow to government departments in the form of daily funds, and most of it will eventually appear in the form of wages. Therefore, the transmission of finance to broader economic growth may be quite high.

Wuzhong, Jiangsu; Dobutamine Hydrochloride Injection and Paramivir Injection are planned to win the bid for the national centralized drug procurement. Jiangsu Wuzhong announced that in the national centralized drug procurement, the bid price of Dobutamine Hydrochloride Injection and Paramivir Injection is 3.58 yuan and 7.47 yuan respectively. The procurement cycle of the two products is until December 31, 2027, and they are supplied to Fujian, Anhui, Jilin, Hubei, Beijing, Inner Mongolia and other provinces and cities respectively. Winning the bid will help to expand the sales of related products, improve market share and brand influence, and have a positive impact on the company's future business performance.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Wuzhong, Jiangsu; Dobutamine Hydrochloride Injection and Paramivir Injection are planned to win the bid for the national centralized drug procurement. Jiangsu Wuzhong announced that in the national centralized drug procurement, the bid price of Dobutamine Hydrochloride Injection and Paramivir Injection is 3.58 yuan and 7.47 yuan respectively. The procurement cycle of the two products is until December 31, 2027, and they are supplied to Fujian, Anhui, Jilin, Hubei, Beijing, Inner Mongolia and other provinces and cities respectively. Winning the bid will help to expand the sales of related products, improve market share and brand influence, and have a positive impact on the company's future business performance.